Collagen Wound Powder Market (2026 - 2033)

Collagen Wound Powder Market Summary

The global collagen wound powder market size was valued at USD 107.5 million in 2025 and is projected to grow from USD 111.5 million in 2026 to USD 145.8 million by 2033, at a CAGR of 3.9% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 44.2% in 2025. The industry is driven by the rising prevalence of diabetic foot ulcers, pressure ulcers, and other chronic wounds.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Increasing adoption of advanced wound-care products and the ability of collagen powders to support tissue regeneration and manage wound exudate are further driving market growth. The rising prevalence of chronic wounds, particularly diabetic foot ulcers, venous leg ulcers, and pressure ulcers, is driving demand for advanced wound-care solutions. Increasing diabetes and aging populations are expanding the patient pool requiring prolonged wound management. Collagen wound powders offer conformability and support the wound-healing process, encouraging their adoption in chronic wound care. For instance, IDF estimates that 589 million adults were living with diabetes globally in 2024, projected to reach 853 million by 2050, expanding the population at risk of diabetic foot ulcers.

To learn more about this report, Download Free Sample Report

According to the European Wound Management Association (EWMA):

• The point prevalence of venous leg ulcers is estimated at 0.33%–1.01% of the population, contributing substantially to the global burden of chronic wound management.

• An estimated 19–34% of people with diabetes are expected to develop diabetic foot disease during their lifetime, driving demand for advanced wound care and infection management solutions.

• Of the estimated 64.3 million people with diabetes in Europe, approximately 16.1 million are expected to develop a diabetic foot ulcer during their lifetime, highlighting the substantial burden of chronic wound care.

The rising prevalence of diabetic foot ulcers (DFUs) is driving demand for collagen wound powders, as diabetes-related complications contribute significantly to chronic, hard-to-heal wounds. Collagen powders are used to support wound-bed management and the healing process in DFUs, particularly in wounds requiring advanced wound-care approaches. The growing diabetic population and increasing clinical focus on preventing wound deterioration and lower-limb complications are expected to further support market growth.

To learn more about this report, Download Free Sample Report

The industry includes collagen-based products supplied in powder or particulate form and intended for direct application to wounds to support wound healing and tissue repair. The market includes pure collagen powders, collagen particulate matrices, and other adjacent powder-form collagen products used in wound-care applications. It excludes collagen sheet dressings, collagen gels, injectable collagen products, and other collagen formulations that are not supplied in powder or particulate form.

Furthermore, the growing adoption of advanced wound-care therapies is driving demand for collagen wound powders as healthcare providers move beyond conventional dressings. Collagen powders offer conformability, exudate management, and support for the wound-healing process, making them suitable for complex and chronic wounds. The increasing availability of collagen-based products and their use across hospital and outpatient wound-care settings are further supporting market growth.

Market Dynamics

The market is driven by the ability of collagen powders to conform to irregular wound beds and support tissue repair. However, relatively high costs and stringent regulatory requirements limit adoption, while novel collagen sources, antimicrobial formulations, and expansion into emerging markets offer growth opportunities.

Market Driver: Increasing Diabetic Population

The increasing diabetic population is driving demand for collagen wound powders due to the higher risk of diabetic foot ulcers and delayed wound healing among these patients. As diabetes prevalence continues to rise globally, the need for effective and convenient advanced wound-care solutions is expanding. Collagen powders support wound management by providing a matrix that can help promote tissue repair, creating further market opportunities.

To learn more about this report, Download Free Sample Report

Market Restraint: High Product Cost

The high cost of collagen wound powders compared with conventional gauze, foam, and other basic dressings can limit their adoption, particularly in cost-sensitive healthcare systems. Manufacturing costs associated with collagen extraction, purification, processing, sterilization, and quality control contribute to higher product prices. Limited reimbursement coverage and out-of-pocket expenses can further restrict use among patients and healthcare providers. This cost barrier is particularly relevant in emerging markets, where healthcare budgets and access to advanced wound-care products remain constrained.

Market Opportunity: Development of Novel Collagen Sources

The development of novel collagen sources, including marine and recombinant collagen, presents significant opportunities for the market. These alternatives can help reduce dependence on conventional bovine and porcine sources while addressing concerns related to disease transmission, allergies, and cultural preferences. Advances in collagen processing also improve product purity, stability, and wound-healing performance. Increasing research into alternative collagen biomaterials could further support the development of next-generation powder formulations.

Market Concentration & Characteristics

The degree of innovation is moderate to high, with manufacturers improving collagen sources, particle characteristics, and formulation technologies. For instance, in July 2026, Ventris Medical’s Collagen Wound Powder received FDA 510(k) clearance, demonstrating continued development of dedicated powder-form wound-care products. Research is also advancing multifunctional collagen formulations with antimicrobial and regenerative properties, supporting the development of next-generation wound-care solutions.

The level of merger and acquisition activity is low to moderate, as the market remains relatively niche and fragmented. M&A activity is primarily driven by broader advanced wound-care and regenerative medicine strategies, rather than collagen powder products alone. Established wound-care companies acquire or partner with smaller biomaterial and collagen technology companies to expand product portfolios, manufacturing capabilities, and access to novel technologies. For instance, in December 2025, MPM Medical acquired a complete collagen manufacturing platform along with the associated FDA 510(k) clearance for surgical collagen devices, expanding its U.S. manufacturing capabilities. The acquisition strengthened the company’s ability to supply American-made collagen products for advanced wound care, surgical applications, and private-label customers.

To learn more about this report, Download Free Sample Report

"With supply chain instability and rising global manufacturing costs, the healthcare market is demanding trustworthy, U.S.-made collagen more than ever," said Marissa Ransdell, MBA, WCSP, Director of Marketing at MPM Medical. "This expansion positions MPM Medical to meet that demand with higher quality control, reduced lead times, and unmatched flexibility for private-label partners."

"By bringing surgical and wound care collagen manufacturing fully in-house, we can innovate faster, scale production responsibly, and provide our partners with reliable, FDA-cleared solutions," said Sudheer Kancherla, Chief Executive Officer. "This is a major milestone not just for MPM Medical, but for every clinician and company seeking dependable, American-made collagen."

Regulations have a moderate to high impact on the market, as products must meet stringent requirements for safety, sterility, biocompatibility, and manufacturing quality. Requirements for animal-derived collagen sourcing and processing can increase development costs and time to market. Regulatory clearances can also create barriers for new entrants while providing established manufacturers with greater market credibility.

The end-use concentration in the market is moderate, with demand primarily concentrated in hospitals, wound care centers, and specialty clinics. These facilities manage a high volume of chronic and complex wounds and have greater access to advanced wound-care products. Home healthcare is an emerging end-use segment, supported by the growing shift toward outpatient and home-based chronic wound management.

Analyst Perspective

The market is a niche but growing segment within advanced wound care, supported by the rising prevalence of chronic wounds and increasing adoption of collagen-based therapies. The market remains fragmented, with established players competing alongside emerging manufacturers offering differentiated collagen sources and formulations. Recent product launches and regulatory clearances are expected to strengthen competition and expand clinical adoption. However, high product costs and regulatory requirements may limit penetration, particularly in price-sensitive markets.

Source Insights

The bovine-derived segment dominated the market with the largest revenue share of 44.1% in 2025, supported by its established use in wound-care formulations and the broad availability of bovine Type I collagen. The segment benefits from well-established processing technologies, clinical familiarity, and the presence of multiple commercially available collagen powder and particulate products. Its established supply chain and relatively broad regulatory experience further support its leading position.

The recombinant/human-derived segment is expected to grow at the fastest rate during the forecast period, supported by increasing research into collagen sources that can reduce concerns associated with animal-derived materials. Advances in recombinant collagen production are enabling improved purity, consistency, and biocompatibility. Growing interest in next-generation regenerative wound-care products is expected to further support the adoption of recombinant and human-derived collagen wound powders.

Product Insights

The pure/native collagen powder segment led the market with the largest revenue share of 64.5% in 2025. Single-source collagen powders, bovine, porcine, and marine, have the longest regulatory track record, the broadest clearance base and the most established body of evidence in chronic wound management, which makes them the first line of choice for routine venous leg ulcers, pressure injuries, donor sites and post-surgical wounds where the primary requirement is a scaffold for granulation rather than an antimicrobial claim. They also carry a materially lower cost per gram than combination formats, a decisive advantage in high-volume, budget-constrained channels such as public hospitals, long-term care, home health, and emerging-market procurement, where reimbursement rarely differentiates between plain and additive-loaded collagen powder.

The composite/combination collagen powder segment is expected to grow at the fastest rate during the forecast period, driven by increasing demand for multifunctional wound-care products that combine collagen with antimicrobial, bioactive, or other regenerative components. These formulations can provide multiple wound-healing benefits while improving product performance across complex and chronic wounds. Growing innovation in combination formulations is expected to support their adoption in diabetic foot ulcers, surgical wounds, and other hard-to-heal wounds.

Application Insights

The chronic wounds segment dominated the market with the largest revenue share of 61.5% in 2025 and is expected to grow at the fastest rate during the forecast period, driven by the rising prevalence of diabetic foot ulcers, pressure ulcers, and venous leg ulcers. Collagen wound powders are being used in chronic wound management because they can conform to irregular wound beds and support the wound-healing process. The growing burden of diabetes, aging populations, and increasing adoption of advanced wound-care therapies is expected to further accelerate demand in this segment.

The acute wounds segment is witnessing significant growth, supported by the increasing incidence of surgical wounds, traumatic injuries, burns, and other acute tissue injuries. Collagen powders offer conformability and ease of application, making them suitable for irregular or difficult-to-cover wound surfaces. Growing adoption of advanced wound-care products in hospitals and outpatient settings is further supporting segment expansion.

Distribution Channel Insights

The direct institutional sales (GPOs/IDNs) segment dominated the market with the largest revenue share of 52.0% in 2025, driven by high procurement volumes from hospitals and surgical centers through centralized purchasing networks. GPOs and IDNs enable healthcare providers to streamline procurement, negotiate favorable pricing, and standardize wound-care products across facilities. The increasing adoption of advanced wound-care therapies in institutional settings is expected to sustain the segment’s leading position.

The specialty /online medical distributors segment is expected to grow at the fastest rate during the forecast period. Growth is supported by increasing digitalization of healthcare procurement and the expanding availability of advanced wound-care products through specialized medical distributors. These channels improve product accessibility for wound-care clinics, home healthcare providers, and smaller healthcare facilities while enabling convenient, efficient replenishment of wound-care supplies.

End-use Insights

The hospitals and surgical centers segment dominated the market with the largest revenue share of 45.3% in 2025, supported by the high volume of surgical wounds, traumatic injuries, burns, and complex chronic wounds treated in these settings. Hospitals and surgical centers have greater access to advanced wound-care products and specialized healthcare professionals, facilitating the adoption of collagen-based wound powders. Increasing surgical procedures and growing emphasis on effective wound management are expected to sustain demand from this end-use segment.

To learn more about this report, Download Free Sample Report

The home care segment is expected to grow at the fastest rate during the forecast period, driven by the increasing shift toward home-based management of chronic and post-surgical wounds. The ease of application and suitability of collagen powders for ongoing wound care can support their use by patients and caregivers under healthcare provider guidance. Rising healthcare costs, shorter hospital stays, and the expansion of home healthcare services are further expected to accelerate segment growth.

Regional Insights

The North America collagen wound powder market dominated and accounted for a revenue share of 44.2% in 2025. The North American market is witnessing strong growth driven by the high prevalence of diabetes and chronic wounds, as well as an established advanced wound-care infrastructure. The region benefits from strong adoption of collagen-based therapies, favorable reimbursement environments, and the presence of leading manufacturers. Continued FDA clearances and product launches are also expanding the availability of collagen powder and particulate wound-care products in the U.S.

To learn more about this report, Download Free Sample Report

U.S. Collagen Wound Powder Market Trends

The collagen wound powder market in the U.S. is supported by the widespread adoption of advanced wound-care therapies. The presence of established manufacturers and specialized wound-care providers further strengthens market development. Recent FDA clearances for collagen powder products, including Ventris Medical’s Collagen Wound Powder in 2026, indicate continued product innovation and commercialization in the U.S. market. The CDC reports that 80% of lower-limb amputations in the U.S. result from diabetes-related complications, highlighting the need for effective wound prevention and management.

Europe Collagen Wound Powder Market Trends

The collagen wound powder market in Europe is driven by the growing burden of an aging population, which often leads to an increasing prevalence of diabetes. According to the European Wound Management Association (EWMA), chronic wounds affect approximately 2.2 individuals per 1,000 population, highlighting a significant healthcare burden across Europe. An increasing focus on cost-effective wound management and the development of innovative collagen formulations are expected to create further opportunities across the region.

The UK collagen wound powder market is expected to grow significantly. As reported by Wounds UK in 2025, the UK National Health Service (NHS) manages approximately 3.8 million chronic wounds annually, with the number of chronic wounds increasing by around 12% each year. The NHS's focus on improving wound management and reducing avoidable complications supports the adoption of advanced wound-care technologies. The growing use of collagen-based dressings in hospitals, community wound-care services, and specialist clinics is contributing to market growth. Increasing healthcare expenditure on chronic wound management and demand for effective healing solutions are expected to create further opportunities.

The collagen wound powder market in France is supported by an aging population requiring long-term wound management. France’s established healthcare infrastructure and increasing adoption of advanced wound-care solutions support demand for collagen-based products. Hospitals & surgical centers, specialist wound-care centers, and home-care services represent important end users. Growing emphasis on improving wound-healing outcomes and reducing complications is expected to support market growth.

Asia Pacific Collagen Wound Powder Market Trends

The collagen wound powder market in Asia Pacific is expected to grow at the fastest CAGR from 2026 to 2033. Expanding healthcare infrastructure and increasing awareness of advanced wound-care products are encouraging adoption across hospitals and specialty clinics. China, Japan, India, South Korea, and Australia represent key markets, while improving access to advanced therapies in emerging Asian economies offers additional opportunities. Increasing local manufacturing of collagen-based wound-care products is also supporting regional market development.

The Japan collagen wound powder market is supported by the country’s aging population, increasing prevalence of diabetes, and growing need for chronic wound management. Japan’s advanced healthcare infrastructure and strong emphasis on innovative medical technologies support the adoption of collagen-based wound-care products. Hospitals & surgical centers and specialized wound-care facilities remain key end users, while Japan’s established medical-device industry supports product development. Increasing demand for effective wound-healing solutions and home-based care is expected to create further opportunities.

Latin America Collagen Wound Powder Market Trends

The collagen wound powder market in Latin America is expected to grow as the prevalence of diabetes and the burden of chronic wounds increase across the region. Brazil represents key markets due to its large patient population and expanding healthcare infrastructure. However, high product costs and differences in healthcare access limit adoption in some countries, creating opportunities for cost-effective locally manufactured products.

MEA Collagen Wound Powder Market Trends

The collagen wound powder market in the Middle East & Africa is expected to expand significantly. Increasing healthcare investments and the development of specialized hospitals and wound-care centers are supporting the adoption of advanced wound-care products. Saudi Arabia, the UAE, and South Africa represent key markets due to improving healthcare infrastructure and growing awareness of advanced therapies. However, limited access to specialized wound care and the relatively high cost of collagen products remain key barriers across several African markets.

Key Collagen Wound Powder Company Insights

The collagen wound powder market is moderately fragmented, with established companies competing alongside emerging regional manufacturers. Leading players benefit from broader wound-care portfolios, established distribution networks, and product innovation, while smaller players compete through specialized formulations and cost-effective products.

Key Collagen Wound Powder Companies:

The following key companies have been profiled for this study on the collagen wound powder market

• Human BioSciences

• Ventris Medical, LLC

• Roosin Medical Co.,Ltd

• Foryou Medical

• EUCARE PHARMACEUTICALS (P) LTD.(International Urgo Medical)

• Synerheal Pharmaceuticals

• ColoGenesis Healthcare Pvt.

• Lotus Surgicals Pvt. Ltd. (Ti Medical Pvt. Ltd.)

• Ovigenex, LLC

• Maiden Biosciences, Inc.

• MPM Medical

• Sanara MedTech Inc. (MIMEDX Group, Inc.)

• Royal Biologics Inc.

• DermaRite Industries, LLC (SionBrands)

• HARTMANN USA, INC.

• MEDLINE

• L&R USA INC.

Recent Developments

• In July 2026, MIMEDX Group, Inc. announced a definitive merger agreement to acquire Sanara MedTech, Inc. in a cash-and-stock transaction valued at USD 35 per Sanara share, representing a total enterprise value of approximately USD 350 million. The transaction is expected to strengthen MiMedx’s position in advanced wound care and expand its complementary product portfolio.

• In October 2024, Royal Wound-X, a division of Royal Biologics, launched two wound-care technologies, Peak Powder Collagen Matrix and ElectroFiber 3D. The launch expanded the company’s wound-care portfolio with innovative technologies designed to support faster and more effective healing. Peak Powder Collagen Matrix is a collagen-based wound-care solution intended for use in both surgical and non-surgical wounds.

• In November 2023, Sanara MedTech Inc. reported the publication of a retrospective study in the Journal of Surgery evaluating CellerateRX Surgical Powder. The study, titled “Activated Collagen Powder Significantly Reduces Surgical Site Infections in Patients Undergoing Elective Surgery,” highlighted the potential of activated collagen powder to reduce surgical site infections and support its application in surgical wound care.

Global Collagen Wound Powder Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global collagen wound powder market report based on source, product, application, end-use, distribution channel and region:

• Source Outlook (Revenue, USD Million, 2021 - 2033)

  • Bovine-Derived

  • Porcine-Derived

  • Marine/Fish-Derived

  • Recombinant / Human-Derived

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Pure / Native Collagen Powder

  • Composite / Combination Collagen Powder

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Chronic Wounds

  • Diabetic Foot Ulcers

  • Pressure Injuries / Ulcers

  • Venous Leg Ulcers

  • Acute Wounds

  • Partial-Thickness Burns (2nd Degree)

  • Traumatic & Surgical Wounds

• End-use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals & Surgical Centers

  • Specialty Wound Care Clinics

  • Long-Term Care / Skilled Nursing Facilities

  • Home care

• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • Direct Institutional Sales (GPOs / IDNs)

  • Specialty Medical Distributors (DME Suppliers)

  • Specialty / Online Medical Distributors

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Sweden

    • Denmark

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The collagen wound powder market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each collagen wound powder segment quantified using the revenue-capture definitions in the table below.